"In women at high risk for breast cancer, a long-term drug treatment can cut the risk of developing the disease in half. Researchers supported by the National Institutes of Health have now identified two gene variants that may predict which wom"...
Patients receiving treatment with MARINOL (dronabinol) Capsules should be alerted to the potential for additive central nervous system depression if MARINOL (dronabinol) Capsules is used concomitantly with alcohol or other CNS depressants such as benzodiazepines and barbiturates.
Patients receiving treatment with MARINOL (dronabinol) Capsules should be specifically warned not to drive, operate machinery, or engage in any hazardous activity until it is established that they are able to tolerate the drug and to perform such tasks safely.
Patients using MARINOL (dronabinol) Capsules should be advised of possible changes in mood and other adverse behavioral effects of the drug so as to avoid panic in the event of such manifestations. Patients should remain under the supervision of a responsible adult during initial use of MARINOL (dronabinol) Capsules and following dosage adjustments.
Last reviewed on RxList: 5/29/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Marinol Information
Marinol - User Reviews
Marinol User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.